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Abstract: Recurrent renal stones occur in ± 7.5% of
Caucasian men and ± 3% of all women. Even with
increasing urbanisation, renal calculi are reported in
less than I% of black South African men and women.
Four hundred recurrent stone formers were studied at
the metabolic stone clinic using routine and special
tests. The appropriate therapy for each subgroup is
outlined and studies on various different treatments
are presented. In addition, lithogenic risk factors were
studied in normal black and white subjects and in
black stone formers, in order to clarify the low
incidence in the black population.
Patients were classified according lO dietary and
metabolic lithogenic risk factors. 10% of stone
formers had pure dietary factors. The percentage of
stone formers in each of the various metabolic
subgroups was as follows: Renal hypercalciuria 12%,
Absorptive hypercalciuria 10%, Mild metabolic
hyperoxaluria 20%, Hypocitraturia 50%. Successful
therapy in terms of preventing further stone
formation was reported using Indapamide, calcium
carbonate and potassium citrate in renal hyper-
calciuria, mild metabolic hyperoxaluria and hypo-
Citraturia respectively. Black volunteer subjects had
significantly higher 24hr urinary sodium excretion
and significantly lower 24hr urinary calcium,' citrate
and cystine excretion than white volunteer subjects.
Twenty-four hours urinary values in black stone
formers were found to be approaching those levels
found in white.
Corre.lpOlldellce and qff"r;II' requests ra: A M Meyers. Chief Physician.
DCpllrimenl of Medicine. Division of Nephrology, 7 York Road. Parktown.
2193. South Africa.
As urbanisation occurs in the black population, the
incidence of urolithiasis would be expected to
increase.
We conclude that a detailed metabolic work-up is
essential in the elucidation of the various metabolic
risk factors. in so-called "idiopathic" CaOx stone
formers. It allows appropriate, specific and highly
cost-effective therapy aimed at the prevention of
recurrence.
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Introduction
Renal calculi occur once in a lifetime in 15% of all
Caucasian men and 6% of all women and recur in
about half of this number. Even with increasing
urbanisation, renal calculi are still reported in < I% of
black South African men and women [I].
Stone formation obeys the laws of thermodynamics.
Thus, in the absence of crystal inhibitors, it is only
when the concentration of solutes in the urine
exceeds the metastable limit, that crystals could
aggregate and grow resulting in large agglomerates
which are the nuclei of stones [2] (Table I).
This study deals with the important aspects which
determined the epidemiological role of the various
promoters and inhibitors in 400 patients with
recurrent calcium oxalate (CaOx) urolithiasis.
Therapeutic strategies used to normalise urinary
concentrations so as to prevent further stone form-
alion is also presented. In addition, the various
lithogenic risk factors were studied in normal black
subjects and black stone formers, in order to clarify
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the reasons of low incidence of kidney stone disease
in the black population.
Table 1. Urinary stone promoters and inhibitors
Promotion Inhibition
Calcium
Sodium
Oxalate
Urate
Cystine
Low pH
Low urine flow
Tamm-horsfall protein
Bacterial products
Magnesium
Pyrophosphate
Citrate
High urine volume
Tamm-Horsfall protein
Nephrocalcin
Glycosaminoglycans
Crystal matrix protein
Methods
Only patients with recurrent renal calculi were
included. Exceptions were made if the patient was
from the black population or was young «20yr). A
thorough medical history, including the number of
stones passed, was taken. A detailed dietary history
with regard to the intake of calcium (Ca), sodium
(Na), phosphate, oxalate, protein, magnesium (Mg),
potassium (K), carbohydrate and fat was conducted
by an experienced dietician. Renal ultrasonography,
tomography and excretory urography were done to
determine the number and size of residual stones and
to exclude medullary sponge kidney,
A full biochemical stone work-up was undertaken.
Briefly, a fasting and post Ig load of calcium, urinary
calcium:creatinine ratio was performed as described
by Pak to distinguish between the various types of
hypercalciuria [3] (Figure I). Standard laboratory
methods were used to measure serum Ca, phosphate,
iCa, creatinine, urea, alkaline phosphatase, uric acid,
cholesterol, liver function, glucose and full blood
count. Serum PTH was measured using an Imrnulite
cherniluminescent enzyme assay (cat. no. LKPH I)
and calcitriol was measured using a Nichols Institute
radioimmunoassay (cat. no. 40-6090). Two 24hr
urines were collected, one on the weekend and one on
a weekday. Urinary Ca, Na, creatinine, urate and
phosphate were measured using standard laboratory
methods, Urinary citrate and oxalate were measured
using Boehringer Mannheim enzyme assay kits
(catalogue number 139076 and 755 699 repectively).
A cyanide-nitroprusside test to exclude homozygous
cystinuria was performed on a spot urine specimen
[4]. An acid load was performed as described by
Wrong and Davies if a 9 am spot urine specimen had
a pH > 5.4 [5]. Titratable acid and ammonia were
determined using standard methods. All available
calculi were sent for wet serru-quantitative chemical
analysis using a Merckognost kit (cat. no. 11003).
More recently, a Coulter Counter Multisizer has been
used to measure crystal growth and aggregation [6].
Results obtained from the Coulter were confirmed
using [14C]-oxalate incorporation experiments and
scanning electron microscopy [7].
Statistical analysis
Means, standard deviations, paired and unpaired T-
tests were performed using Statgraphics (Statistical
Graphics Corporation, Plus*ware).
Fig. 1. Urinary calcium: creatinine ratios in controls, absorptive
hypercalciuric (AHC) and renal hypercalciuric (RHC) stone
formers. before (B) and after (A) a Ig calcium load.
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Results
Lithogenic riskfactors and their treatment
Dietary factors:
a) Pure: By definition these patients had only dietary
factors without any underlying metabolic abnorm-
ality. Dietary aberration as the only risk factor
constituted 10% of 400 patients in the stone popu-
lation, Within this subgroup, 25% had high urinary
Na with concomitant high urinary Ca. Once a normal
salt diet was attained with a urinary excretion or
< I00 - 120 rnmol/day, these patients normalised thei r
urinary calcium (Figure 2).
Twenty percent were found to ingest only excessive
calcium. Once calcium ingestion, particularly abuse
of preparations containing calcium carbonate, was
controlled by restriction to 800-1000 mg/day, normo-
calciuria was attained [8]. It must be stressed that the
commonly given advice of severely restricting
calcium intake is not only fallacious but dangerous
and may lead to, or worsen osteoporosis later on in
life. About 20% had dietary hyperoxaluria and were
completely controlled by a low oxalate diet. The
main food stuffs containing high quantities of oxalate
are, Ceylon tea, green leafy vegetables such as
spinach and rhubarb, coffee and chocolate. A further
20% were persistently drinking little fluid resulting in
low urinary volumes which were highly concentrated.
An increased fluid intake controlled these patients.
Thus, by correcting the dietary aberrations in this
subgroup, stone formation ceased in those who
complied.
Fig. 2. Dietary treatment of patients with urinary sodium> 140
rnrnol / 24hr with standard sodium (I 00mmol/24hr) and calcium
(800-1000mg/24hr) diet.
Patients with renal hypercalciuria were excluded from the
assessment.
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b) Dietary factors in other groups: In all the other
metabolic subgroups described below, 40-50% of the
patients had additional dietary aberrations but 50%
did not [8].
Sub-groups according to metabolic risk factors:
I. Hypercalcaemia: Hypercalcaemia secondary to
primary hyperparathyroidism, sarcoidosis and
various cancers has been noted at our clinic, but
this entity, as a cause for renal stones will not be
discussed further in this paper.
2. Hypercalciuria: This includes those with abso-
rptive (AHC) and renal hypercalciuria (RHC).
Contrary to some reports, our findings agree more
with British researchers in that AHC, whilst being
a possible risk factor, is only a relatively minor
one. In fact, 50% of these patients do not have
hypercalciuria but on calcium:creatinine ratio
tests, they were shown to have normal fasting
levels but an exaggerated response to a calcium
load (Figure I). Therefore they are probably more
at risk to dietary induced hypercalciuria than the
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normal population. Hypercalciuria as a result of
chronic renal calcium loss (RHC), was demon-
strated by increased fasting and post Ca load
ratios and was found in about 12% of all our
patients (Figure I) [8]. The absorption of Ca from
the gut is not disturbed and the cause of the renal
loss is unknown. Previous studies have reco-
mmended a daily dose of 50mg of hydrochlor-
othiazide to normalize hypercalciuria in these
patients. Smaller doses are often not potent
enough even when combined with ameloride.
However, in the doses used, thiazides have
significant side-effects eg. hyperlipidemia, hyper-
uriceamia and carbohydrate intolerance. We have
tested the preparation indapamide (Natrilix)
which, in a dose of 2.5mg daily, has little or no
natriuretic properties and rarely causes the above
side effects. We have shown that it is potently
hypocalciuric and completely corrects the renal
leak in patients with RHC [9].
Potassium wasting continues to be a minor
problem but in the normal population K does not
usually need to be replaced. We strongly
recommend that indapamide should be the drug of
choice in patients with RHC and recurrent calculi.
3. Mild Metabolic Hyperoxaluria (MMHo) MMHo
should not be confused with the condition of
hyperoxaluria/ oxalosis. The defect in MMHo is
not yet fully understood. We and others have
recently theorised that the oxalate digesting
colonic bacteria (oxalobacter formigenes) may be
deficient in patients with recurrent calcium
oxalate calculi [10].
Twenty percent of our patients had MMHo and it
is thus one of the most important risk factors for
recurrent calculi [8]. Treatment however is
problematic. Some mild improvement in some
patients was obtained by decreasing oxalate
ingestion. We and others have tried small,
medium and large doses of pyridoxine but with
limited success (Figure 3). More recently the use
of calcium carbonate has been investigated and
has been found to be successful in some. Calcium
so ingested binds to dietary oxalate thus
preventing free oxalate from being absorbed in
the small and particularly large intestine. The
agent of choice is the simple antacid CaC03 in a
dose of l-Zgm three times a day to be taken with
meals (Table 2). Hypercalciuria must be
monitored for and when it occurs may
occassionally be treated by the addition of
Indapamide. In a small group so treated, the drop
in urinary oxalate treated has been highly
significant (Figure 3).
4. Hypocitraturia: Dietary citrate does not influence
the citrate appearing in the urine [11]. Citrate is
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filtered in the kidney having been formed as one
of the products of the Krebs Cycle and the final
urinary concentration depends on the tubular acid-
base balance. An intracellular acidosis results in
hyperabsorption from the proximal tubule
producing hypocitraturia. Citrate protects against
stone formation as it is an avid chelator of
calcium and also prevents crystal agglomeration
[ 12].
Fig. 3. Assessment of levels of urinary oxalate in patients with
hyperoxaluria before and after treatment with calcium carbonate
and pyridoxine
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This is the most common inorganic defect found
in recurrent calcium oxalate stone formers and
occurred in 50% of all our patients and as an
isolated defect in about 15% [13]. Hypocitraturia
is treated by potassium citrate usually in a dose of
I5-20ml (900mg/5ml) 3x to 4x a day diluted in a
glass of water (Table 2). It is the alkalinising
property of this substance that raises urinary
citrate and not the citrate itself. Potassium citrate
and not sodium citrate is our agent of choice as an
increase in the sodium load may result in
hypernatriuria with concomitant hypercalciuria
and may also possibly worsen hypertension.
Potassium citrate therapy decreased stone form-
ation dramatically in a group of 27 patients
studied over a 3-7 yr. period [14].
5. Cystine: This is a highly insoluble amino acid and
cystinuria is inherited in a complex autosomal
recessive fashion. Homozygous individuals form
many stones. Cystine is only soluble in large
volumes or in urine with a pH > 7.4 [15]. It has
been noted that several patients who formed
calcium oxalate stones also had cystine present in
the stones. Of these, 50% were found to have
urinary cystine in the heterozygous range. In
addition, in six stones analysed from homozygous
cystinurics, 4 were CaOx mixed with cystine and
2 were pure CaOx. This prompted a study using
the Coulter multisizer to examine the effects of
varying concentrations (80-320umol/l) of cystine
on CaOx precipitation, growth and aggregation.
The metastable limit of the urine was not altered
by the increasing cystine concentrations although
increased precipitation of CaOx occurred [16].
Thus epitaxy is unlikely to be the mechanism
involved in the CaOx precipitation by cystine. In
addition, the increasing concentrations of cystine
resulted in increased growth and aggregation of
CaOx. It would appear as though cystine is
"salting out" the CaOx as no cystine crystals were
noted on light or scanning electron microscopy
[16]. Thus cystine may be an important risk factor
in the formation of CaOx stones in heterozygous
cystinurics as well as in parients with low urine
volumes and excreting concentrated unne.
Treatment entails alkalinisation of the urine,
probably with potassium citrate, and a high fluid
intake (Table 2).
6. Uric acid: Pure uric acid stones are rarely seen in
temperate climates today (only one third is
associated with gout). However uric acid
associated with calcium oxalate stones IS
frequently seen. Hyperuricosuria may be due to
an increased ingestion of red meat. More
commonly, uric acid in the stone is associated
with normal urinary uric acid concentration.
However uric acid has been shown to 'salt out'
calcium oxalate especially in acidic urine 1171.
Therefore, the treatment of choice would be to
alkalinise the urine again using potassium citrate.
If an alkaline urine is attained and maintained the
ability of urate to salt out calcium oxalate would
be inhibited. Whether the combination of Allo-
purinol and potassium citrate is more effective
remains to be tested (Table 2).
Table 2. Lithogenic risk factors and their treatment
Risk factor Treatment
Hypercalciuria -Dierary Na
Hypercalciuria- Dietary Ca
Dietary Hyperoxaluria
Low Urine Volume
Hypercalciuria- AHC
Sodium Diet < IOOmmol/day
Calcium Diet 800-1000mg/day
Low Oxalate Diet
Increase Fluid intake
Calcium 800-1000mg/day,
tluid
lndaparnide 2.5 mg/day
Ca Carbonate 1-2gm, 2-Jx
daily with meals Pyridoxine
. 25rng tid
K Citrate 15-20 ml (900 mg/
5ml) 3-4x daily
Fluid, K Citrate
K Citrate and Allopurinol
Hypercalciuria- RHC
MMHo
Hypocitraturia
Cystine
Urate in stones
Other important organic inhibitors
Crystal matrix protein:
This protein has been isolated and sequenced and
found to be the Fl fragment of prothrombin [18].
Using immunohistochemical methods it has been
shown that this protein exists in high concentrations
in proximal tubules, distal tubules and the zona
glomerulosa of the distal convoluted tubule [19]. Its
formation in the kidney is still to be proved using
mRNA probes. In Coulter experiments, it was shown
to be one of the most potent organic inhibitors of
CaOx crystal growth and aggregation [20].
Much work needs to be done to determine the
importance of this inhibitor in normal black and
white subjects as well as patients with recurrent stone
disease.
Glycosaminoglycans and Tamm-Horsfall protein:
The inhibitor or promoter function of these organic
substances need to be further elucidated.
Conflicting reports of both inhibition and promotion
of CaOx formation have been published [7,21]. It is
our intention to examine these substances in the urine
of normal blacks and whites using an ELlSA assay to
determine if any differences are to be found.
Studies in black and white subjects and black and
while stone [ormers
Black and white controls:
Thirty-one semi-urbanised black and 29 urbanised
white subjects were studied using methods described
above.
Black controls diet was significantly higher in
sodium content (p<0.04). There was no difference in
serum results.
Table 4. 24hr urine results in BC, BSF and WSF
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Urinary sodium was significantly higher (p<O.OOOI)
in black controls than in whites.
Urinary potassium, calcium, citrate, phosphate and
cystine were all significantly lower in black controls
than in whites; p<O.OOl, p<O.OOOI, p<O.OOOl,
p<0.0005 and p<0.03 respectively (Table3).
Table 3. Twenty-four hour urine biochemistry in normal black and
white subjects.
Black While
(11=31) (11=29)
Volume ml 1132(413) 1302(444)
Creatinine mrnol 12.0(3.1) 128(3.9)
Sodium mmol 173(63)*** 113(40)
Potassium 11111101 45.5( 16.2)*** 73.4(22.0)
Calcium 11111101 1.53(1.1)*** 3.5 I (2.04)
Phosphate rnmol 18.0(5.7)** 27.3(12.2)
Urate rnrnol 148(0.8) 1.58(0.95)
Oxalate umol 272( 197) 236(132)
Cystine mg 444(214) 717(37.6)
Citrate 11111101 1.58(0.95)*** I 39(0.92)
Mean (SD) is given. Unpaired Ttest p<0.03 *, p<O.OOI **,
p<O.OOOI ***
Certain intrinsic factors in the South African black
may account for the discrepancy in stone formation.
Of these, the very low urinary calcium, significantly
lower urinary cystine and different interactions
between sodium and calcium/cystine are probably of
importance [22].
Black and white stone formers:
Twelve healthy volunteer black males (BC), 21
black stone formers (BSF) and 122 white recurrent
stone formers (WSF) were compared. A standard
metabolic work-up as given in methods was
followed.
BC
(11=12)
Vol (ml)
Na (rnmol)
Ca (mrnol)
1041 (361)*
153(64)
0.96(0.52)***
w 3.63(1.8)
12.5(3.8)
169(4.6
1.06(.72)"
1.22(1.20)
w 3.39(1.1)
239(135)
r=0.23
NS
Creal (rnrnol)
Phos (mrnol)
Urate (rnmol)
Citrate (rrunol)
Oxalate (urnol)
Na.Ca
BSF WSF
(11=2/ ) (11= /22)
1630(717) 1553(607)**
134(58)* 164(54)
3.67(2.06)*** 5.84(2.7)****
14.2(4.0) 16.0(5.3)*
24.3( 13.5)** 34.9( 14.2)****
1.77(.98) 2.00( 1.08)'·
1.04(0.71 )* •• 2.06( I.14)'
309(154) 318(140)
r=0.45, r=0.40
p<0.04 p<O.OOOI
Results expressed as mean (SD). Ttest p<0.04·, p<O.OI •• , p<O.OOI *.', p<O.OOOI**** NS= not significant. w = while controls.
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There were no differences in serum calcium, iCa, and
phosphate. However the PTH and calcitriol levels
were significantly greater in black stone formers as
compared with white stone formers. Serum urate and
creatinine increased in the black stone formers to a
level similar to that found in white stone formers but
higher than the black volunteers. Urinary calcium,
creatinine, phosphate and urate gave values WSF >
BSF > BC. Urinary citrate was lowest in the BSF <
BC < WSF. Urinary volumes were greater in the
stone formers and urinary oxalate was similar in
black and white stone formers, both being greater
than values found in black volunteers (Table 4).
The various categories of risk factors as found in the
black and white stone formers were as follows: Nil
metabolic change in 10% Vs 5%. Metabolic factors
(B= 16 and W=87) including: Renal hypercalciuria
4.5% Vs 10%, absorptive hypercalciuria 4.5% Vs
12%, MMHo 9% Vs 26%, Hypocitraturia 82% Vs
52%.
Pure dietary factors (B=5 and W=35), increased
urinary calcium as a result of increased urinary
sodium 20% Vs 28%, low volume 17% Vs 14%.
Dietary hyperoxaluria and mixed dietary factors were
similar.
It was observed that MMHo was three times more,
RHC and AHC were twice as common in WSF.
Urinary hypocitraturia is the single most common
defect in both groups.
As urbanization occurs, the urine of black stone
formers is becoming more like that of the white stone
formers. Predictably nephrolithiasis will become
more common in the black population [23].
In conclusion, in correctly diagnosed and compliant
patients, stone formation can be significantly
prevented. Thus, although the metabolic work-up is
costly, it is still far more cost effective than repetitive
urological procedures. This concurs with the
conclusions reached by Parks and Coe [24].
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